APA (7th ed.) Citation

T, Y., J, S., K, S., H, M., N, Y., CF, C., . . . K, Y. (2026). Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: Results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-026-01865-0

Chicago Style (17th ed.) Citation

T, Yamanaka, et al. "Quality of Life with Palbociclib Plus Tamoxifen in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: Results from PATHWAY, an Asian International, Double-blind, Randomized Phase 3 Trial." Breast Cancer (Tokyo, Japan) 2026. https://doi.org/10.1007/s12282-026-01865-0.

MLA (9th ed.) Citation

T, Yamanaka, et al. "Quality of Life with Palbociclib Plus Tamoxifen in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: Results from PATHWAY, an Asian International, Double-blind, Randomized Phase 3 Trial." Breast Cancer (Tokyo, Japan), 2026, https://doi.org/10.1007/s12282-026-01865-0.